Variability in the international normalised ratio (INR) in patients with antiphospholipid syndrome and positive lupus anticoagulant: Should the INR targets be higher?

Marielena Baquero-Salamanca, Angélica María Téllez-Arévalo, Carlos Calderon-Ospina

Resultado de la investigación: Contribución a RevistaArtículo

Resumen

We present the case of a 34-year-old woman with a history of antiphospholipid syndrome with triple positivity for antiphospholipid antibodies, who had multiple thrombotic events, predominantly pulmonary embolic events, despite treatment with enoxaparin. She is currently on warfarin, with which she has been adequately controlled most of the time, presenting with only one haemorrhagic event consisting of haematuria and prolonged international normalised ratio (INR) without bleeding. This kind of patient represents a challenge for clinicians, particularly due to INR therapeutic targets, which should be higher than recommended in other patients due to the lupus anticoagulant positivity.
Idioma originalEnglish (US)
PublicaciónBMJ Case Reports
DOI
EstadoPublished - abr 9 2015

Huella dactilar

Lupus Coagulation Inhibitor
International Normalized Ratio
Antiphospholipid Syndrome
Enoxaparin
Antiphospholipid Antibodies
Hematuria
Warfarin
Hemorrhage
Lung
Therapeutics

Citar esto

@article{b3d2e2fc8fc44afb9f314c65fd97ca0b,
title = "Variability in the international normalised ratio (INR) in patients with antiphospholipid syndrome and positive lupus anticoagulant: Should the INR targets be higher?",
abstract = "We present the case of a 34-year-old woman with a history of antiphospholipid syndrome with triple positivity for antiphospholipid antibodies, who had multiple thrombotic events, predominantly pulmonary embolic events, despite treatment with enoxaparin. She is currently on warfarin, with which she has been adequately controlled most of the time, presenting with only one haemorrhagic event consisting of haematuria and prolonged international normalised ratio (INR) without bleeding. This kind of patient represents a challenge for clinicians, particularly due to INR therapeutic targets, which should be higher than recommended in other patients due to the lupus anticoagulant positivity.",
author = "Marielena Baquero-Salamanca and T{\'e}llez-Ar{\'e}valo, {Ang{\'e}lica Mar{\'i}a} and Carlos Calderon-Ospina",
year = "2015",
month = "4",
day = "9",
doi = "10.1136/bcr-2014-209013",
language = "English (US)",
journal = "BMJ Case Reports",
issn = "1757-790X",
publisher = "BMJ Publishing Group",

}

Variability in the international normalised ratio (INR) in patients with antiphospholipid syndrome and positive lupus anticoagulant: Should the INR targets be higher? / Baquero-Salamanca, Marielena; Téllez-Arévalo, Angélica María; Calderon-Ospina, Carlos.

En: BMJ Case Reports, 09.04.2015.

Resultado de la investigación: Contribución a RevistaArtículo

TY - JOUR

T1 - Variability in the international normalised ratio (INR) in patients with antiphospholipid syndrome and positive lupus anticoagulant: Should the INR targets be higher?

AU - Baquero-Salamanca, Marielena

AU - Téllez-Arévalo, Angélica María

AU - Calderon-Ospina, Carlos

PY - 2015/4/9

Y1 - 2015/4/9

N2 - We present the case of a 34-year-old woman with a history of antiphospholipid syndrome with triple positivity for antiphospholipid antibodies, who had multiple thrombotic events, predominantly pulmonary embolic events, despite treatment with enoxaparin. She is currently on warfarin, with which she has been adequately controlled most of the time, presenting with only one haemorrhagic event consisting of haematuria and prolonged international normalised ratio (INR) without bleeding. This kind of patient represents a challenge for clinicians, particularly due to INR therapeutic targets, which should be higher than recommended in other patients due to the lupus anticoagulant positivity.

AB - We present the case of a 34-year-old woman with a history of antiphospholipid syndrome with triple positivity for antiphospholipid antibodies, who had multiple thrombotic events, predominantly pulmonary embolic events, despite treatment with enoxaparin. She is currently on warfarin, with which she has been adequately controlled most of the time, presenting with only one haemorrhagic event consisting of haematuria and prolonged international normalised ratio (INR) without bleeding. This kind of patient represents a challenge for clinicians, particularly due to INR therapeutic targets, which should be higher than recommended in other patients due to the lupus anticoagulant positivity.

U2 - 10.1136/bcr-2014-209013

DO - 10.1136/bcr-2014-209013

M3 - Article

JO - BMJ Case Reports

JF - BMJ Case Reports

SN - 1757-790X

ER -